NDASUBCUTANEOUSSOLUTION
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
7/8 — Comprehensive
ZEMBRACE SYMTOUCH (sumatriptan succinate) by Antares Therapeutics is 5-ht 1b/1d receptors. Approved for migraine, migraine without aura. First approved in 2016.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEMBRACE SYMTOUCH is a subcutaneous sumatriptan succinate solution approved for acute migraine treatment with and without aura. It works as a selective 5-HT1B/1D receptor agonist, causing cranial vasoconstriction and blocking pro-inflammatory neuropeptide release in the trigeminal system.
$0.075MPart D
Peak9.7 years to LOEProduct is in peak lifecycle with modest Part D presence (42 claims), indicating stable but niche market adoption relative to newer competitors.
Mechanism of Action
5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition…
Indications (2)
Worked on ZEMBRACE SYMTOUCH at Antares Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.